Last reviewed · How we verify
Ticagrelor maintenance dose
Ticagrelor is a P2Y12 platelet receptor antagonist that irreversibly blocks ADP-induced platelet aggregation to prevent thrombotic events.
Ticagrelor is a P2Y12 platelet receptor antagonist that irreversibly blocks ADP-induced platelet aggregation to prevent thrombotic events. Used for Acute coronary syndrome (ACS) for reduction of cardiovascular death, myocardial infarction, and stent thrombosis, Secondary prevention of atherothrombotic events in patients with prior myocardial infarction.
At a glance
| Generic name | Ticagrelor maintenance dose |
|---|---|
| Also known as | Ticagrelor, Brilinta |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Drug class | P2Y12 platelet receptor antagonist |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ticagrelor binds directly and reversibly to the P2Y12 adenosine diphosphate (ADP) receptor on platelets, inhibiting platelet activation and aggregation. This prevents clot formation in patients at high risk of cardiovascular events. The maintenance dose is used after an initial loading dose to sustain antiplatelet effects in acute coronary syndrome and other thrombotic conditions.
Approved indications
- Acute coronary syndrome (ACS) for reduction of cardiovascular death, myocardial infarction, and stent thrombosis
- Secondary prevention of atherothrombotic events in patients with prior myocardial infarction
Common side effects
- Bleeding
- Bradycardia
- Dyspnea
- Ventricular pauses
Key clinical trials
- MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study (PHASE4)
- Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention (PHASE4)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA (PHASE3)
- Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA (PHASE3)
- Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease (PHASE4)
- TADCLOT- a Double Blind Randomized Controlled Trial (PHASE3)
- TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ticagrelor maintenance dose CI brief — competitive landscape report
- Ticagrelor maintenance dose updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI